SLC5A2 and Hypoglycemia: Across the entire trial portfolio (n = 23,812) [19,20,21,22,23,24,25,26,27,28,29], SGLT2 inhibitors demonstrated an excellent safety profile with no excess risk of diabetic ketoacidosis, severe hypoglycemia, acute kidney injury, or volume depletion requiring intervention.